Zenas BioPharma Initiates Phase 1 Trial of ZB021, First Oral IL-17 Inhibitor for Autoimmune Diseases
核心洞察
Zenas BioPharma has dosed the first subject in a Phase 1 clinical trial of ZB021 (搜索), a novel oral small molecule IL-17AA (搜索)/AF inhibitor developed in partnership with InnoCare Pharma (搜索).
ZB021 (搜索) represents the first oral IL-17 inhibitor to enter clinical development globally, potentially offering advantages over current biologic therapies in terms of convenience and accessibility.
The Phase 1 study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers, with data expected by year-end 2026 and proof-of-concept results in psoriasis patients anticipated in 2027.
Zenas BioPharma has achieved a significant milestone by dosing the first subject in a Phase 1 clinical trial of ZB021 (搜索), marking the entry of the first oral IL-17 inhibitor into clinical development. The novel small molecule IL-17AA (搜索)/AF inhibitor is being developed in partnership with InnoCare Pharma (搜索) and targets a well-validated pathway across multiple autoimmune and inflammatory conditions.
Novel Mechanism Addresses Unmet Medical Need
ZB021 (搜索) is designed to selectively block the signal transduction pathways of both the IL-17AA (搜索) homodimer and IL-17AF (搜索) heterodimer, inhibiting downstream pro-inflammatory cytokine and chemokine release. Currently, no oral IL-17 inhibitors have been approved or are in late-stage development globally, representing a significant gap in the therapeutic landscape.
"The IL-17 pathway is well validated across a broad range of rheumatic and dermatologic indications, yet no oral therapies directed toward this pathway are approved or in late-stage clinical development," said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. "The strength of this established mechanism may support an accelerated path toward registration-directed trials, and we expect to report initial clinical data by year-end."
Robust Preclinical Foundation
The Phase 1 trial is supported by compelling preclinical data demonstrating ZB021 (搜索)'s potential as a differentiated therapy. Preclinical studies have shown potent anti-inflammatory activity, a favorable safety profile, and excellent Absorption, Distribution, Metabolism, and Excretion (ADME) properties. Notably, excellent oral bioavailability was observed across multiple preclinical species, including non-human primates.
ZB021 (搜索)'s oral, small molecule profile may offer meaningful advantages over currently approved biologic IL-17 therapies in terms of convenience, compliance, and accessibility. The IL-17 pathway has demonstrated broad utility across many rheumatic and dermatologic indications, suggesting potential for multiple therapeutic applications.
Clinical Development Strategy
The Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of single ascending doses (SAD) and multiple ascending doses (MAD) of ZB021 (搜索) in healthy volunteers. The trial is being conducted in partnership with InnoCare Pharma (搜索) in China, with data expected by year-end 2026.
Upon completion and evaluation of the SAD and MAD study, Zenas plans to initiate a proof-of-concept (POC) trial in North America to evaluate clinical activity and safety in psoriasis patients, with results anticipated in 2027. Given the well-established and validated nature of the IL-17 mechanism, Zenas believes there is potential to advance ZB021 (搜索) directly from POC into registration-directed trials, which could meaningfully accelerate the path to regulatory approval.
Strategic Partnership and Licensing
Zenas licensed the exclusive rights from InnoCare Pharma (搜索) to develop, manufacture, and commercialize ZB021 (搜索) in all fields of use worldwide, excluding greater China and Southeast Asia. This partnership leverages InnoCare's expertise in small molecule development while providing Zenas with global commercialization rights for this potentially transformative therapy.
"Dosing the first subject in our Phase 1 trial of ZB021 (搜索) marks an important milestone for Zenas as we rapidly advance our earlier-stage pipeline and broaden our presence in autoimmune and inflammatory diseases," Moulder noted.
Broader Pipeline Context
ZB021 (搜索) represents one component of Zenas BioPharma's comprehensive autoimmune disease portfolio. The company is also advancing two late-stage molecules: obexelimab, a bifunctional monoclonal antibody targeting CD19 (搜索) and FcgRIIb (搜索), and orelabrutinib, a CNS-penetrant BTK (搜索) inhibitor for multiple sclerosis (搜索). Additional earlier-stage programs include ZB022, an oral brain-penetrant TYK2 (搜索) inhibitor, and ZB014, a half-life extended anti-CD19 and FcgRIIb monoclonal antibody.